Search research articles
Contact Us
Filters
Showing results (231-240 of 293) with videos related to
Page
of 30
Sort By:
Vaccines
|
February 26, 2026
Impact of the 2023/24 Influenza Vaccination on Patients with Inflammatory Rheumatic Disease in Germany: Insights from a Nationwide, Longitudinal, Self-Reported Study
Karolina Gente, Benedikt Ditz, Eike Bormann, et al.
Arthritis and Rheumatism
|
April 9, 2005
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)
Christian E Antoni, Arthur Kavanaugh, Bruce Kirkham, et al.
Annals of the Rheumatic Diseases
|
November 18, 2010
Involvement of functional autoantibodies against vascular receptors in systemic sclerosis
Gabriela Riemekasten, Aurélie Philippe, Melanie Näther, et al.
Modern Rheumatology
|
August 3, 2022
Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3)
Tatsuya Atsumi, Yoshiya Tanaka, Tsukasa Matsubara, et al.
Frontiers in Immunology
|
June 27, 2022
Endothelin B Receptor Immunodynamics in Pulmonary Arterial Hypertension
Christoph Tabeling, Carla R González Calera, Jasmin Lienau, et al.
Expert Opinion on Investigational Drugs
|
May 26, 2023
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study
Kyung-Sang Yu, Byungwook Kim, Dongseong Shin, et al.
Annals of the Rheumatic Diseases
|
May 8, 2012
After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?
Richard J Wakefield, Maria Antonietta D'Agostino, Esperanza Naredo, et al.
RMD Open
|
October 19, 2022
A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases
Kastriot Kastrati, Daniel Aletaha, Gerd R Burmester, et al.
Modern Rheumatology
|
April 2, 2022
Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years
Naoki Ishiguro, Yoshiya Tanaka, Tsukasa Matsubara, et al.
Annals of the Rheumatic Diseases
|
October 31, 2019
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019
Kevin L Winthrop, Michael E Weinblatt, Joan Bathon, et al.
Page
of 30
Search research articles
Search
Showing results (231-240 of 293) with videos related to
Sort By:
Page
of 30
Vaccines
|
February 26, 2026
Impact of the 2023/24 Influenza Vaccination on Patients with Inflammatory Rheumatic Disease in Germany: Insights from a Nationwide, Longitudinal, Self-Reported Study
Karolina Gente, Benedikt Ditz, Eike Bormann, et al.
Arthritis and Rheumatism
|
April 9, 2005
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)
Christian E Antoni, Arthur Kavanaugh, Bruce Kirkham, et al.
Annals of the Rheumatic Diseases
|
November 18, 2010
Involvement of functional autoantibodies against vascular receptors in systemic sclerosis
Gabriela Riemekasten, Aurélie Philippe, Melanie Näther, et al.
Modern Rheumatology
|
August 3, 2022
Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3)
Tatsuya Atsumi, Yoshiya Tanaka, Tsukasa Matsubara, et al.
Frontiers in Immunology
|
June 27, 2022
Endothelin B Receptor Immunodynamics in Pulmonary Arterial Hypertension
Christoph Tabeling, Carla R González Calera, Jasmin Lienau, et al.
Expert Opinion on Investigational Drugs
|
May 26, 2023
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study
Kyung-Sang Yu, Byungwook Kim, Dongseong Shin, et al.
Annals of the Rheumatic Diseases
|
May 8, 2012
After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?
Richard J Wakefield, Maria Antonietta D'Agostino, Esperanza Naredo, et al.
RMD Open
|
October 19, 2022
A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases
Kastriot Kastrati, Daniel Aletaha, Gerd R Burmester, et al.
Modern Rheumatology
|
April 2, 2022
Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years
Naoki Ishiguro, Yoshiya Tanaka, Tsukasa Matsubara, et al.
Annals of the Rheumatic Diseases
|
October 31, 2019
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019
Kevin L Winthrop, Michael E Weinblatt, Joan Bathon, et al.
Page
of 30